A Gallup poll suggests nearly 8 million fewer people are obese than in 2022 — a drop that coincides with the surging use of ...

Until recently, GLP -1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World ...

GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.

The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...

The scientists who published the study used gene-editing technology to make the livers of mice produce its own Ozempic-like ...

LOUISVILLE, KY. — A panel representing retail and food processing discussed consumer insights at the recent American Egg Board and United Egg Producers annual joint executive conference in Louisville, ...

The cost of employer-sponsored health insurance rose for the third year in a row in 2025, approaching an average of almost $27,000 for a family plan, according to an annual survey from KFF released ...

Research has suggested the potential of GLP-1 medications for treating substance use disorders, including alcohol, opioids, ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

The U.S. adult obesity rate, calculated as having a BMI of 30 or higher, has gradually declined to 37% in 2025, dropping from ...

The number of people using injectable obesity treatments is increasing rapidly, and it is leading to declines in obesity, ...